Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
TEANECK, N.J., May 07, 2018 -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on June 27, 2018, to stockholders of record at the close of business on June 6, 2018.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com.
Contact:
Richard Johnson
Chief Financial Officer, Phibro Animal Health Corporation
+1 201-329-7300
[email protected]
